

Voyager Therapeutics, Inc.  
Form SC 13G/A  
February 11, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**  
**Under the Securities Exchange Act of 1934**  
**(Amendment No. 1)\***

**Voyager Therapeutics, Inc.**

**(Name of Issuer)**

**Common Stock, \$0.001 par value**

**(Title of Class of Securities)**

**92915B106**

**(CUSIP Number)**

**December 31, 2018**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 92915B106

1. Names of Reporting Persons

SANOFI

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) (b)

3. SEC Use Only

4. Citizenship or Place of Organization

The Republic of France

5. Sole Voting Power

Number of

Shares 0 share

6. Shared Voting Power

Beneficially

Owned by 0 share

Each 7. Sole Dispositive Power

Reporting

Person 0 share

8. Shared Dispositive Power

With

0 share

9. Aggregate Amount Beneficially Owned by Each Reporting Person

0 share

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

0%

12. Type of Reporting Person (See Instructions)

CO

2

### Explanatory Note

This Amendment No. 1 to Schedule 13G is being filed to amend the Schedule 13G filed on February 12, 2016 in order to reflect that the Reporting Person is no longer the beneficial owner of more than five percent of the total number of outstanding Common Stock of the Issuer.

#### Item 1.

- (a) Name of Issuer  
Voyager Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices  
75 Sidney Street, Cambridge, MA 02139

#### Item 2.

- (a) Name of Person Filing  
Sanofi
- (b) Address of Principal Business Office or, if none, Residence  
54 Rue La Boétie, 75008 Paris (France)
- (c) Citizenship  
The Republic of France
- (d) Title of Class of Securities  
Common Stock, \$0.001 par value
- (e) CUSIP Number  
92915B106

#### Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

Edgar Filing: Voyager Therapeutics, Inc. - Form SC 13G/A

- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

- (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:

0 share

- (b) Percent of class:

0%

- (c) Number of shares as to which the person has:

- (i) Sole power to vote or to direct the vote

0 share

- (ii) Shared power to vote or to direct the vote

0 share

- (iii) Sole power to dispose or to direct the disposition of

0 share

- (iv) Shared power to dispose or to direct the disposition of

0 shares

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

In May, 2018, Sanofi on behalf of Aventis Inc. sold all of its shares of Common Stock of the Issuer and is no longer the beneficial owner of Common Stock of the Issuer.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on  
By the Parent Holding Company or Control Person**

Aventis Inc.



**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certifications**

Not applicable.

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 11, 2019  
Date

/s/ Alexandra Roger\*  
Signature

Alexandra Roger

Head of Securities Law and Capital Markets  
Name/Title

\* Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.